Business
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference
-Interim clinical study updates for the first three Subjects treated with BB-301 in the Phase 1b/2a Clinical Treatment Study to be presented as a
About this update from Benitec Biopharma Inc.
[{"type":"text","content":"-Interim clinical study updates for the first three Subjects treated with BB-301 in the Phase 1b/2a Clinical Treatment Study to be presented as a late-breaking oral presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference on March 19, 2025-\nHAYWARD, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (\"ddRNAi\") platform, today announced the acceptance of a late-breaking oral abstract for the BB-301 Phase 1b/2a Clinical Treatment Study ongoing in Subjects diagnosed with Oculopharyngeal Muscular Dystrophy (OPMD) with moderate dysphagia. Interim clinical study updates for the first three Subjects will be discussed in an oral presentation at the Muscular Dystrophy Association Clinical and Scientific Conference on March 19, 2025 at 1:15 pm Central Time. “In October of 2024 we shared interim clinical study data which demonstrated durable, clinically meaningful improvements in swallowing function for the first two Subjects safely treated with BB-301, and we are excited to share updated interim clinical study data with caregivers and families in the OPMD community during the Muscular Dystrophy Association Clinical and Scientific Conference in March,” said Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec. “Dysphagia is a severe, life-threatening complication of OPMD, and our goal is to develop a safe and efficacious treatment which meaningfully reduces the burden of dysphagia. Additional clinical updates for Subjects enrolled in the BB-301 Phase 1b/2a Clinical Treatment Study are planned for the fourth calendar quarter of this year.” Late-Breaking Oral Abstract Presentation: An interim study update for the Phase 1b/2a Clinical Treatment Study of BB-301 in OPMD subjects with moderate dysphagia will be presented in a late-breaking oral presentation entitled “Interim Study Update for the BB-301 Gene Therapy Phase 1b/2a First in Human Trial in Subjects with Oculopharyngeal Muscular Dystrophy with Dysphagia” at 1:15 pm Central Time on March 19th at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference in room Coronado ABCD. Abou...